Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 109

1.

CDC Grand Rounds: National Amyotrophic Lateral Sclerosis (ALS) Registry Impact, Challenges, and Future Directions.

Mehta P, Horton DK, Kasarskis EJ, Tessaro E, Eisenberg MS, Laird S, Iskander J.

MMWR Morb Mortal Wkly Rep. 2017 Dec 22;66(50):1379-1382. doi: 10.15585/mmwr.mm6650a3.

2.

Hydration measured by doubly labeled water in ALS and its effects on survival.

Scagnelli CN, Howard DB, Bromberg MB, Kasarskis EJ, Matthews DE, Mitsumoto HM, Simmons Z, Tandan R; ALS Nutrition-NIPPV Study Group.

Amyotroph Lateral Scler Frontotemporal Degener. 2017 Dec 15:1-12. doi: 10.1080/21678421.2017.1413117. [Epub ahead of print]

PMID:
29243507
3.

Clinical and experimental studies of a novel P525R FUS mutation in amyotrophic lateral sclerosis.

Kuang L, Kamelgarn M, Arenas A, Gal J, Taylor D, Gong W, Brown M, St Clair D, Kasarskis EJ, Zhu H.

Neurol Genet. 2017 Jul 20;3(4):e172. doi: 10.1212/NXG.0000000000000172. eCollection 2017 Aug.

4.

Purpose in life in ALS patient-caregiver dyads: A multilevel longitudinal analysis.

Garcia NE, Morey JN, Kasarskis EJ, Segerstrom SC.

Health Psychol. 2017 Nov;36(11):1092-1104. doi: 10.1037/hea0000507. Epub 2017 May 25.

PMID:
28541074
5.

What lurks in the mind of someone with dysphagia?

Kasarskis EJ.

Muscle Nerve. 2017 Jul;56(1):2-3. doi: 10.1002/mus.25683. Epub 2017 Jun 5. No abstract available.

PMID:
28472864
6.

Fixed dynamometry is more sensitive than vital capacity or ALS rating scale.

Andres PL, Allred MP, Stephens HE, Proffitt Bunnell M, Siener C, Macklin EA, Haines T, English RA, Fetterman KA, Kasarskis EJ, Florence J, Simmons Z, Cudkowicz ME.

Muscle Nerve. 2017 Oct;56(4):710-715. doi: 10.1002/mus.25586. Epub 2017 Mar 21.

PMID:
28120413
7.

ALS mutant SOD1 interacts with G3BP1 and affects stress granule dynamics.

Gal J, Kuang L, Barnett KR, Zhu BZ, Shissler SC, Korotkov KV, Hayward LJ, Kasarskis EJ, Zhu H.

Acta Neuropathol. 2016 Oct;132(4):563-76. doi: 10.1007/s00401-016-1601-x. Epub 2016 Aug 1.

8.

Distinct and shared functions of ALS-associated proteins TDP-43, FUS and TAF15 revealed by multisystem analyses.

Kapeli K, Pratt GA, Vu AQ, Hutt KR, Martinez FJ, Sundararaman B, Batra R, Freese P, Lambert NJ, Huelga SC, Chun SJ, Liang TY, Chang J, Donohue JP, Shiue L, Zhang J, Zhu H, Cambi F, Kasarskis E, Hoon S, Ares M Jr, Burge CB, Ravits J, Rigo F, Yeo GW.

Nat Commun. 2016 Jul 5;7:12143. doi: 10.1038/ncomms12143.

9.

Phenotypic and molecular analyses of primary lateral sclerosis.

Mitsumoto H, Nagy PL, Gennings C, Murphy J, Andrews H, Goetz R, Floeter MK, Hupf J, Singleton J, Barohn RJ, Nations S, Shoesmith C, Kasarskis E, Factor-Litvak P.

Neurol Genet. 2015 Apr 14;1(1):e3. doi: 10.1212/01.NXG.0000464294.88607.dd. eCollection 2015 Jun.

10.

Energy balance: yet another challenge for neurodegenerative diseases.

Kasarskis E.

Lancet Neurol. 2016 Mar;15(3):240-1. doi: 10.1016/S1474-4422(16)00022-3. Epub 2016 Jan 26. No abstract available.

PMID:
26822745
11.

Cognitive-behavioral screening reveals prevalent impairment in a large multicenter ALS cohort.

Murphy J, Factor-Litvak P, Goetz R, Lomen-Hoerth C, Nagy PL, Hupf J, Singleton J, Woolley S, Andrews H, Heitzman D, Bedlack RS, Katz JS, Barohn RJ, Sorenson EJ, Oskarsson B, Fernandes Filho JA, Kasarskis EJ, Mozaffar T, Rollins YD, Nations SP, Swenson AJ, Koczon-Jaremko BA, Mitsumoto H; ALS COSMOS.

Neurology. 2016 Mar 1;86(9):813-20. doi: 10.1212/WNL.0000000000002305. Epub 2016 Jan 22.

12.

Relationship of creatine kinase to body composition, disease state, and longevity in ALS.

Gibson SB, Kasarskis EJ, Hu N, Pulst SM, Mendiondo MS, Matthews DE, Mitsumoto H, Tandan R, Simmons Z, Kryscio RJ, Bromberg MB.

Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(7-8):473-7. doi: 10.3109/21678421.2015.1062516. Epub 2015 Aug 27.

13.

Randomized phase 2 trial of NP001-a novel immune regulator: Safety and early efficacy in ALS.

Miller RG, Block G, Katz JS, Barohn RJ, Gopalakrishnan V, Cudkowicz M, Zhang JR, McGrath MS, Ludington E, Appel SH, Azhir A; Phase 2 Trial NP001 Investigators.

Neurol Neuroimmunol Neuroinflamm. 2015 Apr 9;2(3):e100. doi: 10.1212/NXI.0000000000000100. eCollection 2015 Jun.

14.

NP001 regulation of macrophage activation markers in ALS: a phase I clinical and biomarker study.

Miller RG, Zhang R, Block G, Katz J, Barohn R, Kasarskis E, Forshew D, Gopalakrishnan V, McGrath MS.

Amyotroph Lateral Scler Frontotemporal Degener. 2014 Dec;15(7-8):601-9. doi: 10.3109/21678421.2014.951940. Epub 2014 Sep 5.

15.

Quality improvement in neurology: amyotrophic lateral sclerosis quality measures. Report of the Quality Measurement and Reporting Subcommittee of the American Academy of Neurology.

Miller RG, Brooks BR, Swain-Eng RJ, Basner RC, Carter GT, Casey P, Cohen AB, Dubinsky R, Forshew D, Jackson CE, Kasarskis E, Procaccini NJ, Sanjak M, Tolin FP.

Amyotroph Lateral Scler Frontotemporal Degener. 2014 Jun;15(3-4):165-8. doi: 10.3109/21678421.2013.875706. Epub 2014 Apr 7. No abstract available.

PMID:
24707820
16.

ALS Multicenter Cohort Study of Oxidative Stress (ALS COSMOS): study methodology, recruitment, and baseline demographic and disease characteristics.

Mitsumoto H, Factor-Litvak P, Andrews H, Goetz RR, Andrews L, Rabkin JG, McElhiney M, Nieves J, Santella RM, Murphy J, Hupf J, Singleton J, Merle D, Kilty M, Heitzman D, Bedlack RS, Miller RG, Katz JS, Forshew D, Barohn RJ, Sorenson EJ, Oskarsson B, Fernandes Filho JA, Kasarskis EJ, Lomen-Hoerth C, Mozaffar T, Rollins YD, Nations SP, Swenson AJ, Shefner JM, Andrews JA, Koczon-Jaremko BA; ALS COSMOS Study Group.

Amyotroph Lateral Scler Frontotemporal Degener. 2014 Jun;15(3-4):192-203. doi: 10.3109/21678421.2013.864312. Epub 2014 Feb 24.

17.

Estimating daily energy expenditure in individuals with amyotrophic lateral sclerosis.

Kasarskis EJ, Mendiondo MS, Matthews DE, Mitsumoto H, Tandan R, Simmons Z, Bromberg MB, Kryscio RJ; ALS Nutrition/NIPPV Study Group.

Am J Clin Nutr. 2014 Apr;99(4):792-803. doi: 10.3945/ajcn.113.069997. Epub 2014 Feb 12.

18.

Quality improvement in neurology: amyotrophic lateral sclerosis quality measures: report of the quality measurement and reporting subcommittee of the American Academy of Neurology.

Miller RG, Brooks BR, Swain-Eng RJ, Basner RC, Carter GT, Casey P, Cohen AB, Dubinsky R, Forshew D, Jackson CE, Kasarskis E, Procaccini NJ, Sanjak M, Tolin FP.

Neurology. 2013 Dec 10;81(24):2136-40. doi: 10.1212/01.wnl.0000437305.37850.f9. Epub 2013 Nov 22. Review.

19.

Macroglossia in amyotrophic lateral sclerosis.

McKee HR, Escott E, Damm D, Kasarskis E.

JAMA Neurol. 2013 Nov;70(11):1432-5. doi: 10.1001/jamaneurol.2013.3138.

PMID:
24042440
20.

FUsed in sarcoma is a novel regulator of manganese superoxide dismutase gene transcription.

Dhar SK, Zhang J, Gal J, Xu Y, Miao L, Lynn BC, Zhu H, Kasarskis EJ, St Clair DK.

Antioxid Redox Signal. 2014 Apr 1;20(10):1550-66. doi: 10.1089/ars.2012.4984. Epub 2013 Sep 20.

Supplemental Content

Loading ...
Support Center